Related references
Note: Only part of the references are listed.A Randomized, Placebo-Controlled, Respiratory Syncytial Virus Human Challenge Study of the Antiviral Efficacy, Safety, and Pharmacokinetics of RV521, an Inhibitor of the RSV-F Protein
John DeVincenzo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Lower Respiratory Tract
Francisco M. Marty et al.
CLINICAL INFECTIOUS DISEASES (2020)
A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial of Presatovir for the Treatment of Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic-Cell Transplant Recipients
Roy F. Chemaly et al.
CLINICAL INFECTIOUS DISEASES (2020)
Pharmacokinetics, Safety, and Antiviral Effects of Multiple Doses of the Respiratory Syncytial Virus (RSV) Fusion Protein Inhibitor, JNJ-53718678, in Infants Hospitalized With RSV Infection: A Randomized Phase 1b Study
Federico Martinon-Torres et al.
CLINICAL INFECTIOUS DISEASES (2020)
Discovery of 3-({5-Chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one (JNJ-53718678), a Potent and Orally Bioavailable Fusion Inhibitor of Respiratory Syncytial Virus
Sandrine Vendeville et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus: A Systematic Review
Stephen Mac et al.
PEDIATRICS (2019)
Discovery of Ziresovir as a Potent, Selective, and Orally Bioavailable Respiratory Syncytial Virus Fusion Protein Inhibitor
Xiufang Zheng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
LB6. EDP-938, a Novel RSV N-Inhibitor, Administered Once or Twice Daily Was Safe and Demonstrated Robust Antiviral and Clinical Efficacy in a Healthy Volunteer Challenge Study
Eoin Coakley et al.
Open Forum Infectious Diseases (2019)
State of the Art in Respiratory Syncytial Virus Drug Discovery and Development
G. Stuart Cockerill et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Differential antiviral activities of respiratory syncytial virus (RSV) inhibitors in human airway epithelium
Carmen Mirabelli et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
A Phase 2b Randomized Controlled Trial of Presatovir, an Oral RSV Fusion Inhibitor, for the Treatment of Respiratory Syncytial Virus (RSV) in Lung Transplant (LT) Recipients
J. Gottlieb et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2018)
Antiviral Activity of Oral JNJ-53718678 in Healthy Adult Volunteers Challenged With Respiratory Syncytial Virus: A Placebo-Controlled Study
Marita Stevens et al.
JOURNAL OF INFECTIOUS DISEASES (2018)
A convenient cyclopropanation process of oxindoles via bromoethylsulfonium salt
Hui Qin et al.
TETRAHEDRON (2018)
Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study
Ting Shi et al.
LANCET (2017)
Prolonged viral replication and longitudinal viral dynamic differences among respiratory syncytial virus infected infants
Monica E. Brint et al.
PEDIATRIC RESEARCH (2017)
Animal models of respiratory syncytial virus infection
Geraldine Taylor
VACCINE (2017)
Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor
Dirk Roymans et al.
NATURE COMMUNICATIONS (2017)
Zinc triflate-mediated cyclopropanation of oxindoles with vinyl diphenyl sulfonium triflate: a mild reaction with broad functional group compatibility
Mingwei Zhou et al.
RSC ADVANCES (2017)
Molecular mechanism of respiratory syncytial virus fusion inhibitors
Michael B. Battles et al.
NATURE CHEMICAL BIOLOGY (2016)
Oral GS-5806 Activity in a Respiratory Syncytial Virus Challenge Study
John P. DeVincenzo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Lysosomal Sequestration (Trapping) of Lipophilic Amine (Cationic Amphiphilic) Drugs in Immortalized Human Hepatocytes (Fa2N-4 Cells)
Faraz Kazmi et al.
DRUG METABOLISM AND DISPOSITION (2013)
Hospitalizations Associated With Influenza and Respiratory Syncytial Virus in the United States, 1993-2008
Hong Zhou et al.
CLINICAL INFECTIOUS DISEASES (2012)
Analysis of highly potent amidine containing inhibitors of serine proteases and their N-hydroxylated prodrugs (amidoximes)
Joscha Kotthaus et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2011)
Viral Load Drives Disease in Humans Experimentally Infected with Respiratory Syncytial Virus
John P. DeVincenzo et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2010)
Pharmacologic Advances in the Treatment and Prevention of Respiratory Syncytial Virus
Kerry M. Empey et al.
CLINICAL INFECTIOUS DISEASES (2010)
Acute viral bronchiolitis in children- a very common condition with few therapeutic options
Claire Wainwright
PAEDIATRIC RESPIRATORY REVIEWS (2010)
The influence of drug-like concepts on decision-making in medicinal chemistry
Paul D. Leeson et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease
Timothy F. Feltes et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2007)
RSV604, a novel inhibitor of respiratory syncytial virus replication
Joanna Chapman et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Respiratory syncytial virus fusion inhibitors. Part 5: Optimization of benzimidazole substitution patterns towards derivatives with improved activity
Xiangdong Alan Wang et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
The association between respiratory syncytial virus infection and the development of childhood asthma -: A systematic review of the literature
Eduardo G. Perez-Yarza et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2007)
Respiratory syncytial virus fusion inhibitors. Part 4: Optimization for oral bioavailability
Kuo-Long Yu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
Respiratory syncytial virus infection in elderly and high-risk adults
AR Falsey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Use of a novel cell-based fusion reporter assay to explore the host range of human respiratory syncytial virus F protein
Patrick J. Branigan et al.
VIROLOGY JOURNAL (2005)
Respiratory syncytial virus inhibitors. Part 2: Benzimidazol-2-one derivatives
KL Yu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2004)
Orally active fusion inhibitor of respiratory syncytial virus
C Cianci et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection
C Cianci et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Nucleophilic alkylations of 3-nitropyridines
EJ Andreassen et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2004)
Fluorine in medicinal chemistry
HJ Böhm et al.
CHEMBIOCHEM (2004)
Structural characterization of respiratory syncytial virus fusion inhibitor escape mutants: homology model of the F protein and a syncytium formation assay
CJ Morton et al.
VIROLOGY (2003)
Respiratory syncytial virus - Viral biology and the host response
D Hacking et al.
JOURNAL OF INFECTION (2002)
Share Paper
